Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Pemetrexed/Erlotinib as a Salvage Treatment in Patients with High EGFR-Expressing Metastatic Colorectal Cancer Following Failure of Standard Chemotherapy: A Phase II Single-Arm Prospective Study. 31820199

2020

Entrez Id: 1956
Gene Symbol: EGFR
EGFR
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors. 31679083

2020

Entrez Id: 1956
Gene Symbol: EGFR
EGFR
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Prognostic importance of tumor location and anti-EGFR therapy in patients with K-RAS wild type metastatic colorectal cancer. 31646798

2020

Entrez Id: 1956
Gene Symbol: EGFR
EGFR
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE The development of monoclonal antibodies (mAbs) cetuximab and panitumumab, which target the transmembrane protein epidermal growth factor receptor (EGFR), mark a major step forward in the treatment of metastatic colorectal cancer (mCRC). 30623369

2019

Entrez Id: 1956
Gene Symbol: EGFR
EGFR
Secondary malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer. 30621206

2019

Entrez Id: 1956
Gene Symbol: EGFR
EGFR
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Skeletal muscle loss during anti-EGFR combined chemotherapy regimens predicts poor prognosis in patients with RAS wild metastatic colorectal cancer. 30924091

2019

Entrez Id: 1956
Gene Symbol: EGFR
EGFR
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE <b>Background:</b> Anti-EGFR mAb are recommended treatment for metastatic colorectal cancer (mCRC). 31220949

2019

Entrez Id: 1956
Gene Symbol: EGFR
EGFR
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Patients with <i>HER2</i>-amplified/overexpressed metastatic colorectal cancer (mCRC) harbor a driver actionable molecular alteration that has been shown in preclinical models to hamper efficacy of the anti-epidermal growth factor receptor (EGFR) targeted therapies. 30952821

2019

Entrez Id: 1956
Gene Symbol: EGFR
EGFR
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Cetuximab and panitumumab are two distinct monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR), and both are widely used in combination with chemotherapy or as monotherapy to treat patients with <i>RAS</i> wild-type metastatic colorectal cancer. 31616627

2019

Entrez Id: 1956
Gene Symbol: EGFR
EGFR
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE <b>:</b> Targeting the epidermal growth factor receptor (EGFR) either alone or in combination with chemotherapy in patients with RAS wild type metastatic colorectal cancer (mCRC) has revolutionized the treatment of CRC, but with less results than initially envisaged. 31370270

2019

Entrez Id: 1956
Gene Symbol: EGFR
EGFR
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Patients with metastatic colorectal cancer (mCRC) who fail treatment with standard therapies, including chemotherapy and monoclonal antibodies targeting vascular endothelial growth factor or epidermal growth factor receptor, have few treatment options. 30190299

2019

Entrez Id: 1956
Gene Symbol: EGFR
EGFR
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE The activity of triple-drug chemotherapy regimens when combined with an anti-EGFR mAb in mCRC patients is examined. 30905200

2019

Entrez Id: 1956
Gene Symbol: EGFR
EGFR
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE This review describes the clinical and biological evolution and development of EGFR targeted therapies in mCRC, the challenges in the presence of molecular complexities, the role of cell free (cf)-DNA and future strategies that could lead to further optimal discovery of clinically meaningful biomarkers and application of precision medicine. 31678702

2019

Entrez Id: 1956
Gene Symbol: EGFR
EGFR
Secondary malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE A drug trio consisting of BRAF, MEK, and EGFR inhibitors may become the new standard of care in <i>BRAF</i>-mutant metastatic colorectal cancer. 31591109

2019

Entrez Id: 1956
Gene Symbol: EGFR
EGFR
Secondary malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE Taken together, the superior antitumor efficacy of GC1118 alone or in combination with PI3K/mTOR/AKT inhibitors shows great therapeutic potential for the treatment of <i>KRAS</i>-mutant mCRC with elevated ratios of high- to low-affinity EGFR ligands and PI3K-AKT pathway activation. 31771279

2019

Entrez Id: 1956
Gene Symbol: EGFR
EGFR
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE In this regard, HER2 has emerged as an actionable target in the treatment of mCRC patients with resistance to anti-EGFR therapy. 31164152

2019

Entrez Id: 1956
Gene Symbol: EGFR
EGFR
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Treatments in this setting can include regorafenib (an oral multikinase inhibitor), trifluridine/tipiracil hydrochloride (TAS-102), antibodies that target epidermal growth factor receptor for patients with RAS wild-type tumors (if no prior exposure), and, where approved, anti-programmed cell death protein 1 inhibitors for patients with microsatellite instability-high mCRC. 30598357

2019

Entrez Id: 1956
Gene Symbol: EGFR
EGFR
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE <b>Expert commentary:</b> Fruquintinib was approved for patients with metastatic colorectal cancer (RAS wild type) who have previously received fluorouracil, oxaliplatin, and irinotecan-based chemotherapy and who have received or are not suitable for anti- VEGF therapy and anti- EGFR therapy. 31177854

2019

Entrez Id: 1956
Gene Symbol: EGFR
EGFR
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Therefore, we performed this review to summarize the available data regarding the optimal sequential treatment of anti-EGFR and -VEGF mAb for RAS or KRAS WT mCRC and discuss the potential mechanisms that may explain this phenomenon. 30863179

2019

Entrez Id: 1956
Gene Symbol: EGFR
EGFR
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE KRAS and NRAS mutations are identified resistance mutations to anti-epidermal growth factor receptor monoclonal antibodies in patients with metastatic colorectal cancer. 30811471

2019

Entrez Id: 1956
Gene Symbol: EGFR
EGFR
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Rechallenge with anti-EGFR provides clinical benefit in molecularly selected mCRC patients beyond second line. 30616224

2019

Entrez Id: 1956
Gene Symbol: EGFR
EGFR
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Co-expression and prognostic significance of putative CSC markers CD44, CD133, wild-type EGFR and EGFRvIII in metastatic colorectal cancer. 30899442

2019

Entrez Id: 1956
Gene Symbol: EGFR
EGFR
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE The present study focuses on the involvement of EGFR positive and negative feedback genes in the establishment of cetuximab (CTX) resistance in metastatic Colorectal Cancer (CRC) patients. 31052457

2019

Entrez Id: 1956
Gene Symbol: EGFR
EGFR
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Monoclonal antibodies targeting epidermal growth factor receptor (EGFR) or vascular endothelial growth factor (VEGF) have demonstrated efficacy with chemotherapy (CT) as second line treatment for metastatic colorectal cancer (mCRC). 31443300

2019

Entrez Id: 1956
Gene Symbol: EGFR
EGFR
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Combining tivantinib, an inhibitor of the MET receptor tyrosine kinase, and cetuximab may be effective in patients with epidermal growth factor receptor-resistant MET-high mCRC. 30846365

2019